Jun 1, 2024 • 10:00 am EDT SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
May 30, 2024 • 8:00 am EDT Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
May 23, 2024 • 5:05 pm EDT Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
May 9, 2024 • 8:00 am EDT Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 7, 2024 • 8:00 am EDT Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 24, 2024 • 4:05 pm EDT Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Apr 2, 2024 • 8:00 am EDT Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Mar 12, 2024 • 8:00 am EDT Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Mar 6, 2024 • 8:00 am EST Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit